Back to Directory
Imiglucerase
Performance & EnduranceEnzyme replacement therapy for Gaucher disease.
Key Benefits
- ✓Treats Gaucher disease
- ✓Reduces organomegaly
- ✓Improves blood counts
- ✓Reduces bone disease
- ✓Enzyme replacement
Dosing Information
Dosage Range
2.5-60 units/kg
Frequency
Every 2 weeks
Typical Duration
Lifelong
Detailed Protocol
Administered via intravenous infusion every 2 weeks. Dosing individualized based on disease severity. Infusion center. Lifelong therapy.
About Imiglucerase
Imiglucerase (Cerezyme) is recombinant glucocerebrosidase for enzyme replacement in Gaucher disease type 1. Modified to target macrophages. FDA-approved for this lysosomal storage disorder.
Research Notes
FDA-approved in 1994. First ERT for Gaucher disease. Revolutionized treatment. Multiple alternative products now available. Lifelong therapy.
Potential Side Effects
- •Infusion reactions
- •Antibody formation
- •Pruritus
- •Flushing
- •Generally well tolerated
Always consult with a healthcare professional before starting any peptide therapy.